title: EFFECTS OF LIRAGLUTIDE 3.0 MG ON WEIGHT AND RISK FACTORS IN HISPANIC VERSUS NON-HIPANIC POPULATIONS: SUBGROUP ANALYSIS FROM SCALE RANDOMIZED TRIALS.
abstract: Scarce data exist on pharmacotherapy for obesity in Hispanic individuals. This post hoc analysis of pooled data from 4 phase 3a trials compared the efficacy and safety of liraglutide 3.0 mg versus placebo, as adjunct to a reduced-calorie diet and physical activity, in Hispanic versus non-Hispanic subgroups.
  
  
  
  We conducted the double-blind randomized, placebo-controlled trials in adults with a minimum body mass index (BMI) of 27 kg/m2with at least 1 comorbidity, or a minimum BMI of 30 kg/m2, at clinical research sites worldwide. In this analysis, we investigated possible differences in treatment effects between 534 Hispanics (10.4% of the population) and 4,597 non-Hispanics (89.6%) through statistical tests of interaction between subgroups and treatment. Variables examined included mean and categorical weight change, cardiovascular risk markers, and safety data.
  
  
  
  Both subgroups achieved clinically significant mean weight loss at end-of-treatment with liraglutide 3.0 mg versus placebo: Hispanics 7.0% versus 1.5%, treatment difference -5.1% (95% CI, -6.2 to -4.0); non-Hispanics 7.5% versus 2.3%, -5.2% (95% CI, -5.5 to -4.8). More individuals in both subgroups lost ≥5%, >10%, and >15% of their baseline weight with liraglutide 3.0 mg than with placebo. Efficacy endpoints generally did not vary with ethnicity (P>.05). Adverse events were comparable between ethnic subgroups, with more gastrointestinal disorders reported with liraglutide 3.0 mg than placebo.
  
  
  
  Efficacy and safety were largely similar between Hispanic and non-Hispanic subgroups. Results support that liraglutide 3.0 mg, used with a reduced-calorie diet and physical activity, can facilitate weight loss in Hispanic individuals.
  
  
  
  A1c = glycated hemoglobin BMI = body mass index CI = confidence interval FPG = fasting plasma glucose GLP-1 = glucagon-like peptide-1 hsCRP = high-sensitivity C-reactive protein SCALE = Satiety and Clinical Adiposity - Liraglutide Evidence in individuals with and without diabetes T2DM = type 2 diabetes mellitus.
authors.forename: Patrick M
authors.initials: PM
authors.lastname: O'Neil
authors.forename: W Timothy
authors.initials: WT
authors.lastname: Garvey
authors.forename: J Michael
authors.initials: JM
authors.lastname: Gonzalez-Campoy
authors.forename: Pablo
authors.initials: P
authors.lastname: Mora
authors.forename: Rafael Violante
authors.initials: RV
authors.lastname: Ortiz
authors.forename: German
authors.initials: G
authors.lastname: Guerrero
authors.forename: Birgitte
authors.initials: B
authors.lastname: Claudius
authors.forename: Xavier
authors.initials: X
authors.lastname: Pi-Sunyer
mesh_terms: D000328:Adult; D015897:Comorbidity; D004311:Double-Blind Method; D005260:Female; D006630:Hispanic or Latino; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D000069450:Liraglutide / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D008297:Male; D008875:Middle Aged; D009765:Obesity / Q000188:drug therapy / Q000208:ethnology; D017063:Outcome Assessment, Health Care; D050177:Overweight / Q000188:drug therapy* / Q000208:ethnology; D012307:Risk Factors; D015431:Weight Loss / Q000187:drug effects*
chemical_list: D007004:Hypoglycemic Agents; D000069450:Liraglutide